Literature DB >> 33253686

Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Chathur Acharya1, Jasmohan S Bajaj2.   

Abstract

Chronic liver disease is reaching epidemic proportions with the increasing prevalence of obesity, nonalcoholic liver disease, and alcohol overuse worldwide. Most patients are not candidates for liver transplantation even if they have end-stage liver disease. There is growing evidence of a gut microbial basis for many liver diseases, therefore, better diagnostic, prognostic, and therapeutic approaches based on knowledge of gut microbiota are needed. We review the questions that need to be answered to successfully translate our knowledge of the intestinal microbiome and the changes associated with liver disease into practice.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Diet; Fecal Microbial Transplant; Hepatic Encephalopathy

Mesh:

Year:  2020        PMID: 33253686      PMCID: PMC9026577          DOI: 10.1053/j.gastro.2020.10.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  153 in total

1.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

2.  Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.

Authors:  Jasmohan S Bajaj; I Jane Cox; Naga S Betrapally; Douglas M Heuman; Mitchell L Schubert; Maiyuran Ratneswaran; Phillip B Hylemon; Melanie B White; Kalyani Daita; Nicole A Noble; Masoumeh Sikaroodi; Roger Williams; Mary M E Crossey; Simon D Taylor-Robinson; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-09-25       Impact factor: 4.052

3.  Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.

Authors:  Jasmohan S Bajaj; Genta Kakiyama; Tor Savidge; Hajime Takei; Zain A Kassam; Andrew Fagan; Edith A Gavis; William M Pandak; Hiroshi Nittono; Phillip B Hylemon; Prapaporn Boonma; Anthony Haag; Douglas M Heuman; Michael Fuchs; Binu John; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatology       Date:  2018-09-20       Impact factor: 17.425

4.  Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.

Authors:  Jasmohan S Bajaj; Zain Kassam; Andrew Fagan; Edith A Gavis; Eric Liu; I Jane Cox; Raffi Kheradman; Douglas Heuman; Jessica Wang; Thomas Gurry; Roger Williams; Masoumeh Sikaroodi; Michael Fuchs; Eric Alm; Binu John; Leroy R Thacker; Antonio Riva; Mark Smith; Simon D Taylor-Robinson; Patrick M Gillevet
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

5.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

Review 6.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

7.  Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant.

Authors:  Runping Liu; Jason D Kang; R Balfour Sartor; Masoumeh Sikaroodi; Andrew Fagan; Edith A Gavis; Huiping Zhou; Phillip B Hylemon; Jeremy W Herzog; Xiaojiaoyang Li; Robert H Lippman; Javier Gonzalez-Maeso; James B Wade; Siddhartha Ghosh; Emily Gurley; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.298

8.  Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; Joel L Steinberg; Sarah Hobgood; Peter A Boling; Michael Godschalk; Saima Habib; Melanie B White; Andrew Fagan; Edith A Gavis; Dinesh Ganapathy; Phillip B Hylemon; Karen E Stewart; Raffi Keradman; Eric J Liu; Jessica Wang; Patrick M Gillevet; Masoumeh Sikaroodi; F Gerard Moeller; James B Wade
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

9.  Targeting Gut Microbiome Interactions in Service-Related Gastrointestinal and Liver Diseases of Veterans.

Authors:  Jasmohan S Bajaj; Arun Sharma; Pradeep K Dudeja
Journal:  Gastroenterology       Date:  2019-08-09       Impact factor: 22.682

Review 10.  Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

Authors:  Chencheng Xie; Dina Halegoua-DeMarzio
Journal:  Nutrients       Date:  2019-11-19       Impact factor: 5.717

View more
  14 in total

1.  Predicting development of ACLF.

Authors:  Jordan Hindson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09       Impact factor: 46.802

Review 2.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

3.  Small phenolic and indolic gut-dependent molecules in the primate central nervous system: levels vs. bioactivity.

Authors:  George E Jaskiw; Dongyan Xu; Mark E Obrenovich; Curtis J Donskey
Journal:  Metabolomics       Date:  2022-01-06       Impact factor: 4.290

4.  Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.

Authors:  Krishnakant Saboo; Nikita V Petrakov; Amirhossein Shamsaddini; Andrew Fagan; Edith A Gavis; Masoumeh Sikaroodi; Sara McGeorge; Patrick M Gillevet; Ravishankar K Iyer; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-11-15       Impact factor: 25.083

Review 5.  Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.

Authors:  Elke Roeb
Journal:  Visc Med       Date:  2021-10-26

6.  Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis.

Authors:  Mario R Álvares-da-Silva; Claudia P Oliveira; Andrew Fagan; Larisse Longo; Rutiane U Thoen; Patricia M Yoshimura Zitelli; Renee M Tanaka Ferreira; Sara Mcgeorge; Amirhossein Shamsaddini; Alberto Q Farias; Masoumeh Sikaroodi; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2021-04-02       Impact factor: 11.382

7.  The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD/CCL4-induced murine model of liver injury.

Authors:  Shahrbanoo Keshavarz Azizi Raftar; Fatemeh Ashrafian; Sara Abdollahiyan; Abbas Yadegar; Hamid Reza Moradi; Morteza Masoumi; Farzam Vaziri; Arfa Moshiri; Seyed Davar Siadat; Mohammad Reza Zali
Journal:  Sci Rep       Date:  2022-02-14       Impact factor: 4.996

8.  Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.

Authors:  Martha D Gay; Hong Cao; Narayan Shivapurkar; Sivanesan Dakshanamurthy; Bhaskar Kallakury; Robin D Tucker; John Kwagyan; Jill P Smith
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 6.208

Review 9.  Regulatory mechanism of HIF-1α and its role in liver diseases: a narrative review.

Authors:  Qingfei Chu; Xinyu Gu; Qiuxian Zheng; Haihong Zhu
Journal:  Ann Transl Med       Date:  2022-01

Review 10.  Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer.

Authors:  Chenchen Bi; Geqiong Xiao; Chunyan Liu; Junwei Yan; Jiaqi Chen; Wenzhang Si; Jian Zhang; Zheng Liu
Journal:  Front Cell Dev Biol       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.